| Range: | 25.18-42.73 | Vol Avg: | 7587 | Last Div: | 0.07 | Changes: | 0.98 |
| Beta: | 0.88 | Cap: | 0.12B | Currency: | USD | Exchange: | AMEX |
| Sector: | Financial Services | IPO: | Wed Dec 31 2014 | Empoloyees: | |||
| CUSIP: | 00162Q593 | CIK: | 0001414040 | ISIN: | US00162Q5936 | Country: | US |
SBIO 38.65 Stock Price ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow